Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 4 | 13 | +0,06 % | ||
| WAVE LIFE SCIENCES | 3 | 2 | 0,00 % | ||
| INCYTE | 2 | 25 | +1,00 % | ||
| HUTCHMED | 2 | 7 | 0,00 % | ||
| REGENERON PHARMACEUTICALS | 1 | 22 | +0,42 % | ||
| BEONE MEDICINES LTD ADR | 1 | 10 | -0,72 % | ||
| LYELL IMMUNOPHARMA | 1 | 8 | -0,82 % | ||
| GILEAD SCIENCES | 1 | 5 | -0,06 % | ||
| STRUCTURE THERAPEUTICS | 1 | 1 | +5,21 % | ||
| ANAVEX LIFE SCIENCES | 1 | - | +0,90 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02:24 | Regeneron Reports Promising Phase 1/2 Data Of Lynozyfic In Newly Diagnosed Multiple Myeloma | 23 | AFX News | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic (linvoseltamab) in adults with newly diagnosed... ► Artikel lesen | |
| 02:12 | HUTCHMED Medicines Renewed In NRDL And Added To New Commercial Insurance Drug List | 125 | AFX News | LONDON (dpa-AFX) - HUTCHMED (China) Limited (HCM) announced that following the renewal of its contract with the China National Healthcare Security Administration (NHSA), the updated National... ► Artikel lesen | |
| 01:06 | HUTCHMED (China) Limited: HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China | 5 | GlobeNewswire (USA) | ||
| 01:01 | HUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED ANNOUNCES EXPANDED COVERAGE ON NATIONAL REIMBURSEMENT DRUG LIST AND INCLUSION IN THE FIRST COMMERCIAL ... | 2 | HKEx | ||
| 00:24 | Structure Therapeutics Inc.: Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 | 1 | GlobeNewswire (USA) | ||
| 00:06 | BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features | 2 | Benzinga.com | ||
| So | Regeneron Pharmaceuticals, Inc.: Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment | 10 | GlobeNewswire (USA) | ||
| So | Lyell Immunopharma, Inc: Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition | 2 | GlobeNewswire (USA) | ||
| So | Adipositas-Studie: Wave Life Sciences vor Veröffentlichung wichtiger Zwischendaten | 4 | Investing.com Deutsch | ||
| So | Wave Life Sciences to announce interim obesity drug trial data | 1 | Investing.com | ||
| So | Wave Life Sciences Ltd.: Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025 | 2 | GlobeNewswire (USA) | ||
| So | Incyte Gets FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug | 4 | Investor's Business Daily | ||
| So | Bei Bayer kehrt die Hoffnung zurück, Novo Nordisk kämpft mit noch mehr Konkurrenz, Eli Lilly dreht an der Preisschraube und BioNTech meldet Studienerfolg | 986 | NTG24.de | Die ansonsten stets vielbeachteten Pharma-Aktien standen in diesem Jahr ein wenig im Schatten von KI und Rüstung, doch langweilig wurde es im Segment dennoch nur selten. Zum Jahresende scheinen sich... ► Artikel lesen | |
| So | ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch | 3 | FierceBiotech | ||
| So | FDA fast-tracks Incyte drug for rare blood cancer | 14 | Seeking Alpha | ||
| So | Wochenend-Analyse: Biontech-Aktie vor entscheidender Woche - Montag könnte alles ändern! | Hebelschein-Spekulant | |||
| So | Lymphom-Studie: Genmabs EPKINLY senkt Progressionsrisiko um 79 % | 10 | Investing.com Deutsch | ||
| So | Genmab: Epcoritamab-Kombination senkt Risiko bei follikulärem Lymphom um 79 % | 3 | Investing.com Deutsch | ||
| So | Genmab's EPKINLY plus R2 shows 79% reduced disease progression risk in lymphoma trial | 3 | Investing.com | ||
| So | Prime Medicine, Inc.: Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease | 1 | GlobeNewswire (USA) |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .